Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Antiretroviral therapy modifies the genetic effect of known type 2 diabetes-associated risk variants in HIV-infected women.

Frasco MA, Karim R, Van Den Berg D, Watanabe RM, Anastos K, Cohen M, Gange SJ, Gustafson DR, Liu C, Tien PC, Mack WJ, Pearce CL.

AIDS. 2014 Jul 31;28(12):1815-23. doi: 10.1097/QAD.0000000000000366.

PMID:
24932614
[PubMed - in process]
2.

Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study.

Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, Young M, Justman JE.

AIDS. 2007 Aug 20;21(13):1739-45.

PMID:
17690572
[PubMed - indexed for MEDLINE]
3.

Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994-2011.

Tripathi A, Jerrell JM, Liese AD, Zhang J, Rizvi AA, Albrecht H, Duffus WA.

Metab Syndr Relat Disord. 2013 Dec;11(6):417-26. doi: 10.1089/met.2013.0017. Epub 2013 Aug 2.

PMID:
23909647
[PubMed - indexed for MEDLINE]
4.

Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.

Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS.

Cochrane Database Syst Rev. 2013 Mar 28;3:CD005481. doi: 10.1002/14651858.CD005481.pub3. Review.

PMID:
23543540
[PubMed - indexed for MEDLINE]
5.

Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.

Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Egger M, Weber R; Swiss HIV Cohort Study.

Clin Infect Dis. 2007 Jul 1;45(1):111-9. Epub 2007 May 21.

PMID:
17554711
[PubMed - indexed for MEDLINE]
Free Article
6.

Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.

Guo JJ, Jang R, Louder A, Cluxton RJ.

Pharmacotherapy. 2005 Aug;25(8):1044-54.

PMID:
16207094
[PubMed - indexed for MEDLINE]
7.

Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women.

Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, Weber K, Piessens E, Robison E, Anastos K.

J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):298-302.

PMID:
12626890
[PubMed - indexed for MEDLINE]
8.

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102.

PMID:
19282782
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
[PubMed - indexed for MEDLINE]
10.

Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time.

Tripathi A, Liese AD, Jerrell JM, Zhang J, Rizvi AA, Albrecht H, Duffus WA.

Diabet Med. 2014 Oct;31(10):1185-93. doi: 10.1111/dme.12455. Epub 2014 Apr 28.

PMID:
24673640
[PubMed - in process]
11.

The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study.

Howard AA, Hoover DR, Anastos K, Wu X, Shi Q, Strickler HD, Cole SR, Cohen MH, Kovacs A, Augenbraun M, Latham PS, Tien PC.

J Acquir Immune Defic Syndr. 2010 Jun;54(2):152-9. doi: 10.1097/QAI.0b013e3181d0c911.

PMID:
20190642
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.

Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ.

HIV Med. 2005 Nov;6(6):396-402.

PMID:
16268821
[PubMed - indexed for MEDLINE]
13.

Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.

Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.

Clin Infect Dis. 2008 Jan 15;46(2):305-12. doi: 10.1086/524752.

PMID:
18171267
[PubMed - indexed for MEDLINE]
Free Article
14.

Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.

Mocroft, Horban, Clumeck, Stellbrink, Monforte dA, Zilmer, Kirk, Gatell, Phillips, Lundgren; EuroSIDA Study Group.

HIV Clin Trials. 2006 Nov-Dec;7(6):271-84.

PMID:
17208897
[PubMed - indexed for MEDLINE]
Free Article
15.

Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.

Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.

AIDS. 2006 Oct 3;20(15):1941-50.

PMID:
16988515
[PubMed - indexed for MEDLINE]
16.

Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study.

Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, Young M, Justman JE.

J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):369-76.

PMID:
19186350
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.

Shey M, Kongnyuy EJ, Shang J, Wiysonge CS.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005481. doi: 10.1002/14651858.CD005481.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;3:CD005481.

PMID:
19588374
[PubMed - indexed for MEDLINE]
18.

Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors.

Sankatsing RR, Wit FW, Vogel M, de Groot E, Brinkman K, Rockstroh JK, Kastelein JJ, Stroes ES, Reiss P.

Atherosclerosis. 2009 Feb;202(2):589-95. doi: 10.1016/j.atherosclerosis.2008.05.028. Epub 2008 May 28.

PMID:
18599064
[PubMed - indexed for MEDLINE]
19.

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.

Mallal SA, John M, Moore CB, James IR, McKinnon EJ.

AIDS. 2000 Jul 7;14(10):1309-16.

PMID:
10930144
[PubMed - indexed for MEDLINE]
20.

The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.

Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C, Geretti AM; UK HIV Drug Resistance Database; UK CHIC study.

AIDS. 2013 Sep 10;27(14):2245-53. doi: 10.1097/QAD.0b013e3283636179.

PMID:
24157905
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk